Atara, Imeka Team Up to Bring Advanced Imaging to ATA188 Trial

Atara, Imeka Team Up to Bring Advanced Imaging to ATA188 Trial

316115

Atara, Imeka Team Up to Bring Advanced Imaging to ATA188 Trial

Atara Biotherapeutics has partnered with Imeka to use its proprietary biomarker imaging technology in the ongoing EMBOLD Phase 2 clinical trial, which is investigating ATA188 for the treatment of progressive forms of multiple sclerosis (MS). The imaging technology will be used to determine if Atara’s ATA188 can effectively reduce inflammation and restore myelin in the brain and spinal cord of people with primary and secondary progressive MS (PPMS and SPMS). Myelin is a fatty substance surrounding nerve…

You must be logged in to read/download the full post.